ACAD Stock Recent News
ACAD LATEST HEADLINES
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on August 5, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 63,477 shares of common stock and 49,377 restricted stock units (“RSUs”) to twenty-six new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees'.
ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Al Kildani - Corporate Participant Catherine E. Owen Adams - CEO & Director Elizabeth H.
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.2 per share a year ago.
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2025. “Acadia continued to build momentum in the second quarter, resulting in total revenue of $264.6 million,” said Catherine Owen Adams, Chief Executive Officer. “NUPLAZID delivered a very strong quarter, particularly in terms of referrals and new patient starts, driven by strong commercial execution and increased engagement from our direct-to-cons.
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Scott Cenci as Senior Vice President, Chief Information and Data Officer. In this role, Scott will lead Acadia's digital transformation including technology, data and AI strategy and will serve as a member of the company's Executive Leadership Team, reporting to Catherine Owen Adams, Chief Executive Officer of Acadia. “We are thrilled to welcome Scott to Acadia,” said Catherine Owen Adams.
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR (GMAB) and Acadia Pharmaceuticals (ACAD). But which of these two stocks offers value investors a better bang for their buck right now?
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ACADIA's valuation is justified by strong revenue growth from NUPLAZID and DAYBUE, with total 2025 revenue guidance of $1B–$1.1B. ACP-101's phase 3 trial for Prader-Willi syndrome is a high-risk catalyst, with a 60–65% probability of success due to improved trial design. We believe ACP-101's market potential is lower than consensus, estimating $400M peak revenue due to late market entry and dosing frequency.